Atossa Therapeutics, Inc. entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants. The combined offering price is $3.30 per share, with the company expecting net proceeds of approximately $4.1 million after expenses. The warrants have an exercise price of $4.40 per share and could provide an additional $12 million in gross proceeds if fully exercised. Rodman & Renshaw LLC is serving as the exclusive placement agent. Net proceeds are intended for clinical development, working capital, and general corporate purposes. Atossa Therapeutics is a biopharmaceutical company focused on developing therapeutic products.